|
T. A. Bogush, A. A. Basharina, A. M. Scherbakov, K. I. Chandran, A. L. Mikhailova, I. P. Romanov, E. A. Bogush, V. S. Kosorukov
Tumor
cell panel with characterized expression of PD-L1 for preclinical studies of
anticancer drugs and immune checkpoint inhibitors interaction
Abstract
PD-L1 (Programmed death-ligand 1), a
membrane protein of the immunoglobulin superfamily, is one of the targets for
cancer immunotherapy. A panel of 14 cancer cell cultures with different
constitutive PD-L1 expression level was formed and characterized. The panel is
recommended for preclinical studies of a cytostatic drug effect on PD-L1
expression and for predicting the efficacy of their combination with immune
checkpoint inhibitors.
Key words: PD-L1, immunotherapy, oncology, chemotherapy, tumor
cell panel, cytostatic drugs
Copyright (C) Chemistry Dept., Moscow State University, 2002
|
|
